[go: up one dir, main page]

Tomić et al., 2017 - Google Patents

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

Tomić et al., 2017

View HTML
Document ID
10219190470189289608
Author
Tomić T
Olausson J
Wilzén A
Sabel M
Truvé K
Sjögren H
Dósa S
Tisell M
Lannering B
Enlund F
Martinsson T
Åman P
Abel F
Publication year
Publication venue
PLoS One

External Links

Snippet

Pilocytic astrocytoma (PA) is the most common pediatric brain tumor. A recurrent feature of PA is deregulation of the mitogen activated protein kinase (MAPK) pathway most often through KIAA1549-BRAF fusion, but also by other BRAF-or RAF1-gene fusions and point …
Continue reading at journals.plos.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for mutation or polymorphism detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6802—General aspects
    • C12Q1/6809—Sequence identification involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Tomić et al. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma
Helmsauer et al. Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma
Parolia et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Hu et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing
Ulz et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
Flavahan et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
Fittall et al. Recurrent rearrangements of FOS and FOSB define osteoblastoma
Picco et al. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
Cajuso et al. Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival
Li et al. Somatic SF3B1 hotspot mutation in prolactinomas
McGuire et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas
Cin et al. Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project Zhang Jinghui 1 Wu Gang 1 Miller Claudia P 2 Tatevossian Ruth G 3 Dalton James D 3 Tang Bo 3 Orisme Wilda 3 Punchihewa Chandanamali 3 Parker Matthew 1 Qaddoumi Ibrahim 4 Boop Fredrick A 5 Lu Charles 6 Kandoth Cyriac 6 Ding Li 7 Lee Ryan 3 Huether Robert 1 Chen Xiang 1 Hedlund Erin 1 Nagahawatte Panduka 1 Rusch Michael 1 Boggs Kristy 8 Cheng Jinjun 3 Becksfort Jared 1 Ma Jing 3 Song Guangchun 3 Li Yongjin 1 Wei Lei 3 Wang Jianmin 9 Shurtleff Sheila 3 Easton John 8 Zhao David 1 Fulton Robert S 6 Fulton Lucinda L 6 Dooling David J 6 Vadodaria Bhavin 8 Mulder Heather L 8 Tang Chunlao 1 Ochoa Kerri 6 Mullighan Charles G 3 Gajjar Amar 4 Kriwacki Richard 10 Sheer Denise 11 Gilbertson Richard J 2 Mardis Elaine R 6 Wilson Richard K 6 Downing James R 3 Baker Suzanne J 2 Ellison David W david. ellison@ stjude. org 3 bc Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
Majewski et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
US9216172B2 (en) Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
Shao et al. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma
Barathova et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype
Alvarez-Garcia et al. A simple and robust real-time qPCR method for the detection of PIK3CA mutations
Oh et al. Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas
Wang et al. SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1α signaling
Jones et al. The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis
Yadav et al. Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians
Buganim et al. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype
Valouev et al. Discovery of recurrent structural variants in nasopharyngeal carcinoma
Chou et al. B-Myb induces APOBEC3B expression leading to somatic mutation in multiple cancers